Ewha Womans University Medical Center
Myeloma treatment cost in the Republic of Korea typically begins with essential diagnostics such as an extended analysis of blood, which runs from $100 to $200. Patients may also require a consultation with a hematologist ranging from $100 to $300. Total expenses depend on the disease stage, the necessity of stem cell transplants, and the specific line of therapy. Patients from the US can save approximately 30-50% on advanced oncological care. Seoul remains the primary destination for these medical services.
Typical Myeloma Treatment Costs in Republic of Korea
Bookimed Expert Insight: For complex cases, multidisciplinary centers like Seoul National University Hospital (SNUH) offer the highest cancer treatment statistics in the country. Patients seeking the most advanced digital care should consider Seoul National University Bundang Hospital (SNUBH), Korea's first fully digital hospital. Large facilities like Asan Medical Center are best for those needing high-volume surgical expertise. These JCI-accredited institutions provide world-class oncology protocols with significantly lower out-of-pocket costs than American hospitals.
| Republika Korei | Turcja | Austria | |
| Plazmafereza | od $4,200 | od $1,200 | od $2,000 |
Państwo nie płacą za usługi Bookimed. Ceny leczenia szpiczaka mnogiego odpowiadają cennikowi kliniki. Płatność dokonywana jest bezpośrednio w klinice po przyjeździe. Dostępna jest płatność w ratach.
Bookimed dba o Państwa bezpieczeństwo. Współpracujemy tylko z klinikami spełniającymi wysokie międzynarodowe standardy w leczeniu szpiczaka mnogiego. Posiadają one wymagane licencje do obsługi pacjentów międzynarodowych na całym świecie.
Bookimed oferuje bezpłatną pomoc i wsparcie. Osobisty koordynator medyczny pozostaje w kontakcie przed, w trakcie i po podróży. Nie będą Państwo sami w innym kraju podczas leczenia szpiczaka mnogiego.
Kangnam Severance Hospital — to największy wielospecjalistyczny szpital w Seulu (Korea Południowa).
Specjalizacja — onkologia, neurochirurgia, neurologia, kardiologia i check-up (kompleksowe badania).
Klinika jako jedna z pierwszych w Seulu otrzymała amerykańską akredytację Joint Commission International. To potwierdza przestrzeganie międzynarodowych standardów bezpieczeństwa leczenia i stosowanie nowoczesnych metod.
Wśród osiągnięć centrum medycznego — pierwszy przeszczep płuc w Korei Południowej.
Seoul St. Mary hospital, Seoul National University Hospital, and Asan Medical Center lead multiple myeloma care in South Korea. These centers utilize advanced hematopoietic stem cell transplantation and early CAR-T cell therapy. Leading facilities hold JCI accreditation and maintain high hematologic malignancy survival rates.
Bookimed Expert Insight: Data shows a major volume gap between specialized university hospitals and local centers. Patients should focus on the Big Four hospitals in Seoul like Asan Medical Center or Seoul National University Hospital. These centers handle the highest volume of cancer procedures. High patient volume directly correlates with better outcomes in complex stem-cell transplants.
Patient Consensus: Patients emphasize choosing Seoul university hospitals over regional centers for complex blood cancer care. Access to specialized hematology teams and transplant expertise are the most critical factors mentioned.
CAR T-cell therapy is available for multiple myeloma in South Korea at major academic cancer centers. Treatment is primary indicated for relapsed or refractory cases. Most access occurs through approved advanced therapies or ongoing clinical trials like CARTITUDE-5. Facilities typically hold JCI or KOIHA accreditations.
Bookimed Expert Insight: South Korea is a leader in digitalized medicine. Seoul National University Hospital has been fully digital since 2004. This technical maturity allows clinics to manage the complex data tracking required for individual CAR T-cell batches. High patient volumes at centers like Asan Medical Center, which sees over 11,000 outpatients daily, provide the necessary expertise for handling rare treatment reactions.
Patient Consensus: Patients note that qualifying for treatment takes time and requires pre-screening at a major university hospital. They emphasize the need to stay close to the clinic for several weeks to monitor for specific side effects after the cells are returned.
South Korean hospitals monitor myeloma success using standardized protocols and national data-driven analysis. Facilities like Seoul National University Bundang Hospital employ advanced digital systems to prevent medical errors. Clinicians prioritize rapid adoption of novel therapies and triplet regimens to improve longitudinal survival and risk-stratified care.
Bookimed Expert Insight: While many countries focus on outpatient care, South Korean centers like Asan Medical Center manage high patient volumes, serving over 2,500 inpatients daily. This scale allows for rapid data collection of real-world evidence. Their digital infrastructure, such as the BESTcare system, ensures that treatment adjustments are documented instantly, which is critical for myeloma patients who require frequent dosing changes.
Patient Consensus: Patients note that Korean doctors focus on aggressive side effect management to keep treatment on schedule. They value regular lab checks that monitor kidney health alongside tumor markers as a sign of comprehensive care.
South Korea provides advanced myeloma treatments including CAR-T cell therapy, quadruplet induction regimens, and novel XPO1 inhibitors like Selinexor. JCI-accredited centers in Seoul utilize autologous stem cell transplants and specialized techniques like double filtration plasmapheresis to manage complex cases and relapsed disease effectively.
Bookimed Expert Insight: Major academic centers like Seoul National University Hospital and Asan Medical Center handle massive patient volumes, often exceeding 180,000 annually. This high intensity translates to deep expertise in managing transplant-eligible patients. When choosing a facility, prioritize centers with KOIHA or JCI accreditation, as these typically offer the most streamlined referral pathways for breakthrough CAR-T treatments.
Patient Consensus: Patients note that arriving at a large academic center early is vital for securing eligibility for clinical trials and newer cell therapies. They emphasize that proper bone protection and kidney monitoring are just as critical as the main treatment regimen.
International patients can obtain remote second opinions from South Korean oncology centers before traveling. Specialists at JCI-accredited facilities evaluate diagnostic images and pathology records through secure portals. This process confirms diagnoses and treatment eligibility. It helps patients determine if traveling to Seoul is necessary.
Bookimed Expert Insight: While many patients target major centers based on ranking, the highest success often correlates with massive patient volume. Asan Medical Center treats over 180,000 patients annually and maintains a 90% success rate for complex procedures. Choosing these high-volume tertiary hospitals ensures that remote opinions come from specialists who handle thousands of myeloma cases every year.
Patient Consensus: Patients note it is important to have complete medical records ready before requesting a review. They emphasize that while remote opinions help with travel decisions, doctors often wait until arrival to finalize plans after re-reading original pathology slides.